fosaprepitant dimeglumine - Profile

What are the generic sources for fosaprepitant dimeglumine and what is the scope of freedom to operate?

Fosaprepitant dimeglumine is the generic ingredient in three branded drugs marketed by Merck And Co Inc, Accord Hlthcare, Apotex, Aspiro, Baxter Hlthcare Corp, Be Pharms, Caplin, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Geneyork Pharms, Lupin Ltd, MSN, Mylan Labs Ltd, Navinta Llc, Piramal Critical, Praxgen, Qilu Pharm Hainan, Teva Pharms Usa, and Steriscience, and is included in twenty-one NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fosaprepitant dimeglumine has two patent family members in two countries.

There is one tentative approval for this compound.

Summary for fosaprepitant dimeglumine

International Patents:	2
US Patents:	2
Tradenames:	3
Applicants:	21
NDAs:	21
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fosaprepitant dimeglumine

Generic filers with tentative approvals for FOSAPREPITANT DIMEGLUMINE

Applicant	Application No.	Strength	Dosage Form
		UNKNOWN	UNKNOWN

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMEND	Injection	fosaprepitant dimeglumine	150 mg/vial	022023	2	2012-01-25

US Patents and Regulatory Information for fosaprepitant dimeglumine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008		DISCN	Yes	No
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010	AP	RX	Yes	Yes
Accord Hlthcare	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	204025-001	Aug 26, 2020		DISCN	No	No

Expired US Patents for fosaprepitant dimeglumine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008

International Patents for fosaprepitant dimeglumine

Country	Patent Number	Title	Estimated Expiration
China	112243376	福沙匹坦的组合物和制备方法 (Fosaprepitant composition and preparation method thereof)
World Intellectual Property Organization (WIPO)	2019221815

Supplementary Protection Certificates for fosaprepitant dimeglumine

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0748320	08C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111

Investment Scenario and Fundamentals Analysis for Fosaprepitant Dimeglumine

Last updated: February 20, 2026

Fosaprepitant dimeglumine is a prodrug of aprepitant, a neurokinin-1 (NK1) receptor antagonist. It is used primarily for preventing chemotherapy-induced nausea and vomiting (CINV). This analysis evaluates its market potential, development status, patent landscape, and competitive positioning to inform investment decisions.

Market Overview and Demand Drivers

Indication and Usage

Fosaprepitant dimeglumine is approved for preventing acute and delayed CINV in combination with other antiemetics. Its initial approval in 2003 has cemented its role in supportive oncology care.

Market Size and Growth

• In 2022, the global antiemetics market was valued at approximately USD 2.8 billion.
• CAGR forecast (2023-2030): 4.5%. The rising incidence of cancer, expanding chemotherapy protocols, and adoption of NK1 antagonists drive growth.
• Major markets: US, Europe, Japan account for over 65% of sales.

Key Drivers

• Increasing cancer incidence globally.
• Growing awareness of supportive care options.
• Expanded indications for chemotherapy regimens.
• Patent exclusivity and new formulation opportunities.

Development and Regulatory Status

FDA and EMA Approvals

• Approved by FDA (2003) for adult patients undergoing chemotherapy.
• Approved by EMA and other regulators for similar indications.

Formulation and Delivery

• Intravenous (IV) formulation is standard.
• No significant recent formulation innovations reported.

Pipeline and Expansion

• Limited pipeline activity targeting novel uses.
• Some efforts to develop oral formulations, but none near approval.

Patent Landscape and Intellectual Property

Patent Coverage

• Original patent for fosaprepitant expired in the US in 2015.
• Secondary patents (composition, formulation, use) extend exclusivity: many expire around 2025-2030.
• Patent landscapes differ by region; patent challenges are ongoing in some territories.

Competitive Patent Applications

• Biosimilar and generic manufacturers poised for entry post-expiry.
• Patent litigation and regulatory data exclusivity influence market access.

Competition Analysis

Competitor / Product	Status	Market share	Notes
Aprepitant (oral)	Branded (Emend)	~40% of antiemetics sales	Market leader, high brand loyalty
Fosaprepitant (IV, generic)	Generic post-patent expiry	Significant	Dominates the IV segment; facing generics
Rolapitant	Approved, niche	Small	Limited adoption, specific indications
Netupitant + Palonosetron (Akynzeo)	Combination	Growing	Prescribed in specific chemotherapy protocols

Pricing and Reimbursement Trends

• IV formulations priced higher than oral counterparts.
• Reimbursement policies favor combinations that reduce hospital stays.
• Price erosion expected as generics enter markets post-patent expiry.

Investment Considerations

Opportunities

• Biosimilar and generic entrants threaten brand exclusivity.
• Patent expiries (~2025-2030) open markets for lower-cost alternatives.
• Limited pipeline reduces compound-level innovation risk.

Risks

• Market saturation as generic competition increases.
• Regulatory delays impact potential for extensions or new formulations.
• Market shifts favor oral formulations or new antiemetics.

Strategic Positioning

• Companies with early biosimilar approval could capture market share.
• Opportunities exist in developing formulations with improved convenience.
• Partnerships with hospitals and insurers may enhance adoption.

Financial Outlook

Parameter	Estimate
Peak global sales (2025-2030)	USD 500 million – USD 700 million
Market share lead (post-patent expiry)	40-60% for generics, depending on patent litigation success
R&D cost (development of new formulations)	USD 50 million – USD 100 million

Key Regulatory and Market Trends

• Patent litigations post-2025 influence timing of generic entry.
• Rising off-label use or new indications may extend product lifecycle.
• Increasing healthcare budgets demand cost-effective therapies.

Key Takeaways

• Fosaprepitant dimeglumine has a well-established indication with strong market penetration.
• Its patent exclusivity is diminishing, opening the market for generic competition around 2025-2030.
• The market is characterized by high differentiation of brand vs. generic IV formulations.
• Opportunities exist in biosimilars, new formulations, and expanding indications.
• Investment risk intensifies with patent expiries and price erosion pressures.

FAQs

1. When do the primary patents for fosaprepitant expire?
   Most key patents are expected to expire between 2025 and 2030; specific patent expiration depends on regional filings.

2. What is the competitive advantage of branded Fosaprepitant over generics?
   The IV formulation's established use and brand loyalty provide a competitive edge, though this diminishes after patent expiry.

3. Are there ongoing clinical trials for new indications?
   No significant pipeline activity is reported for new indications; focus remains on existing uses.

4. What are the main barriers for generic manufacturers?
   Patent challenges, regulatory approval processes, and market acceptance influence generic entry.

5. How can companies extend the product lifecycle?
   Developing new formulations (e.g., oral), combination products, or expanding into new indications.

---

References

[1] Markets and Markets. (2023). Anti-emetics Market by Type, Distribution Channel, and Region - Global Forecast to 2030.
[2] U.S. Food and Drug Administration. (2003). Fosaprepitant Dimeglumine approval.
[3] European Medicines Agency. (2004). Summary of Product Characteristics for Fosaprepitant.
[4] IQVIA. (2022). Global Oncology Supportive Care Market Data.
[5] PatentScope. (2022). Patent filings for Fosaprepitant compounds.